These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3935458)

  • 1. Naloxone inhibits sulpiride-induced hyperprolactinaemia in man.
    Bernini GP; Pedrinelli R; Salvetti A; Franchi F; Luisi M
    Eur J Clin Invest; 1985 Oct; 15(5):272-5. PubMed ID: 3935458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women.
    Fioretti P; Cagnacci A; Paoletti AM; Gambacciani M; Soldani R; Mauro GA; Spinetti A; Melis GB
    J Endocrinol Invest; 1989 May; 12(5):295-301. PubMed ID: 2549113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postreceptorial refractoriness of prolactin release mechanisms.
    Collu R; Ducharme JR; Eljarmak D; Marchisio AM; Bertrand J; Sabbagh I; Guillaumot P; Cohen H
    Can J Physiol Pharmacol; 1983 Jul; 61(7):676-84. PubMed ID: 6616329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia.
    Massara F; Camanni F; Martra M; Dolfin GC; Müller EE; Molinatti GM
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):103-10. PubMed ID: 6851194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxone reduces the fenfluramine-induced prolactin release in man.
    Foresta C; Scanelli G; Indino M; Federspil G; Scandellari C
    Clin Endocrinol (Oxf); 1985 Apr; 22(4):539-43. PubMed ID: 3987071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.
    Massara F; Camanni F; Belforte L; Campagnoli C; Novi RF; Molinatti GM
    Acta Endocrinol (Copenh); 1980 Oct; 95(2):145-50. PubMed ID: 7435113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
    Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxone does not modify fenfluramine-induced prolactin increase in obese patients.
    Argenio GF; Bernini GP; Vivaldi MS; del Corso C; Santoni R; Franchi F
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):505-8. PubMed ID: 1769132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unresponsiveness of prolactin to repeated injection of sulpiride in man.
    Cohen H; Pugeat M; Tourniaire J; Bertrand J
    Eur J Clin Pharmacol; 1983; 25(2):275-7. PubMed ID: 6628512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma.
    Hanew K; Utsumi A; Sugawara A; Shimizu Y; Yoshinaga K
    Acta Endocrinol (Copenh); 1991 May; 124(5):545-52. PubMed ID: 1903012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioidergic and dopaminergic effects on LH and prolactin release in pony mares at different times of the year.
    Aurich C; Parvizi N; Brunklaus D; Hoppen HO; Aurich JE
    J Reprod Fertil Suppl; 2000; (56):195-203. PubMed ID: 20681131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin but not dopamine is involved in the naloxone-induced luteinizing hormone release in man.
    Foresta C; Scanelli G; Tramarin A; Scandellari C
    Fertil Steril; 1985 Mar; 43(3):447-50. PubMed ID: 3979585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the GABAergic drug, sodium valproate, on the prolactin release evoked by pharmacological stimuli in normal women.
    Melis GB; Fruzzetti F; Paoletti AM; Mais V; Beneventi F; Trimarchi G; Fioretti P
    Clin Endocrinol (Oxf); 1984 Mar; 20(3):245-52. PubMed ID: 6426828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin responsiveness to repeated decremental doses of sulpiride.
    Tormey WP; Buckley MP; Taaffe W; O'Kelly DA; Darragh A
    Horm Metab Res; 1981 Aug; 13(8):454-5. PubMed ID: 7327523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine.
    Nair NP; Lal S; Thavundayil JX; Isaac I; Eugenio H; Achim A; Schwartz G; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):633-7. PubMed ID: 4089188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a dose-dependent effect in the sex-specific plasma prolactin response to naloxone in humans.
    Monteleone P; Marano E; Steardo L
    Boll Soc Ital Biol Sper; 1983 Apr; 59(4):469-75. PubMed ID: 6882542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible mixed agonist--antagonist activity of D-sulpiride at dopamine receptor level in man.
    Benfenati F; Bernardi P; Cortelli P; Capelli M; Adani C; Calzà L; Agnati LF
    Neurosci Lett; 1981 Nov; 26(3):289-95. PubMed ID: 7033836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone, prolactin and cortisol nyctohemeral variations during naloxone-induced opiate receptor blockade in man.
    Delitala G; Giusti M; Rodriguez G; Mazzocchi G; Ferrini S; Baccelliere L; Montano V; Rosadini G; Giordano G
    Acta Endocrinol (Copenh); 1982 Jul; 100(3):321-6. PubMed ID: 6287782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential responses in prolactin levels induced by naloxone in humans.
    Steardo L; Monteleone P; Tamminga CA; Canonico PL; Denman D; Scapagnini U; Chase TN
    Psychoneuroendocrinology; 1985; 10(2):203-9. PubMed ID: 4034850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of postnatal gonads in the maturation of dopaminergic regulation of prolactin secretion in female rats.
    Watanobe H; Takebe K
    Endocrinology; 1987 Jun; 120(6):2212-9. PubMed ID: 3569131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.